Product Description
SRT-055 is representative of a first-in-class CNS-penetrant, dual LRRK2/ASK1 inhibitor series designed to treat diseases of the central nervous system, including Parkinson's. The LRRK2 kinase is a promising disease-modification kinase target with a genetic connection to Parkinson's disease. Mutations in LRRK2 that are associated with aberrantly enhanced kinase activity are the most common cause of genetic Parkinson's disease (10% of cases). New evidence suggests elevated LRRK2 kinase activity without LRRK2 mutations in idiopathic forms of the disease. Lysosomal dysfunction is a central pathology of Parkinson’s disease. Excessive LRRK2 activity results in lysosomal dysfunction that results in the accumulation of toxic products that cause cell damage. (Sourced from: https://www.sealrocktx.com/science.html)
Mechanisms of Action: ASK1 Inhibitor,LRRK2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Seal Rock Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Amyotrophic Lateral Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|